Agouron Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Agouron Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Agouron Pharmaceuticals: 10 sponsored US clinical trials, none currently recruiting.
Agouron Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cytomegalovirus Retinitis, with 1 trials.
Top-decile sponsor footprint
Agouron Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
10 total, page 1 of 1
Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir
NCT00006326
A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
NCT00006211
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy
NCT00004985
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
NCT00002169
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3
NCT00002185
Viracept Expanded Access Program
NCT00002165
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
NCT00002170
Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants
NCT00002164
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
NCT00005001
A Study of Viracept in HIV-Positive Women
NCT00002171
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
Therapeutic Areas
How the Agouron Pharmaceuticals early-phase archive is shaped
10 indexed studies, none listed as recruiting (0% open); 9 completed (90%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Cytomegalovirus Retinitis (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Agouron Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Agouron Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 archived trials
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Aimmune Therapeutics · 10 trials · 10% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Agouron Pharmaceuticals page
10 registered trials is a research-attention snapshot, not an endorsement of Agouron Pharmaceuticals or any single study.
- None of Agouron Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cytomegalovirus Retinitis is the condition Agouron Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cytomegalovirus Retinitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Agouron Pharmaceuticals pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.